Crewe Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Crewe Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150	Closed	-$1K	–	476
2020 Q4	$1K	Hold	150	–	–	﹤0.01%	431
2020 Q3	$0	Hold	150	–	–	﹤0.01%	629
2020 Q2	$0	Hold	150	–	–	﹤0.01%	222
2020 Q1	$0	Hold	150	–	–	﹤0.01%	219
2019 Q4	$1K	Hold	150	–	–	﹤0.01%	248
2019 Q3	$0	Buy	+150	New	+$464	﹤0.01%	278

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's LXRX Position: Q1 2021 in Review

Crewe Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2021, closing a stake of 150 shares — an estimated $1K sold.

Crewe Advisors first reported a position in LXRX in Q3 2019 and held it in 6 quarters. The position peaked at $1K in Q4 2020. 107 funds tracked by Wall St. Rank hold LXRX as of Q1 2021.

Crewe Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Crewe Advisors sold 150 Lexicon Pharmaceuticals shares in Q1 2021, an estimated $1K.
Crewe Advisors first reported a position in Lexicon Pharmaceuticals in Q3 2019 and held it in 6 quarters.
Crewe Advisors's Lexicon Pharmaceuticals position peaked at $1K in Q4 2020.
107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2021.

Based on Crewe Advisors's 13F filing for Q1 2021, filed 21 Apr 2021.